NSABP B-47: A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles) of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel to Chemotherapy Plus Trastuzumab
CTO - 6723
Cancer - Breast
Principal Investigator: Thomas J Doyle, MD
This trial is studying chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer. Giving more than one drug or combination chemotherapy, and giving chemotherapy after surgery may kill more tumor cells.
- Must be female at least 18 years of age
- Tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination; all staging criteria must be met
- Patient must have undergone either a total mastectomy or breast conserving surgery